(NUVA) Alere Extends Deal with Virtua – Analyst Blog
March 09, 2013
Alere Inc. (ALR), a medical products company focused on integrating rapid diagnostics with health... Visit StockBlogHub to view complete post. Read More
from Stock Blog Hub
Healthcare Stocks Recap: Novadaq Technologies Inc, HEALTHSOUTH Corp, Alere Inc, Spectrum Pharmaceuticals
March 08, 2013
Medical Laboratories and Research Stocks Review: Waters Corporation, PerkinElmer, NeoGenomics, Alere Inc
February 26, 2013
4 Stocks Are Declining Sharply (HK, OSUR, ALR, KORS)
November 08, 2012
Top Losers U.S Stock of This Hour (TNK, OEH, ALR, WIN)
November 08, 2012
Stock Market Edges Into Positive Column
October 03, 2012
Up/Downgrades
May 24, 2012
New York, May 24th (TradersHuddle.com) - Research Analyst's early calls ahead of the bell. Eaton Vance ( NYSE:EV ) was upgraded to a Neutral from Sell at Citigroup. Aeropostale (<a href="http:. Read... Read More
from TradersHuddle.com
Abaxis Remains Neutral
May 23, 2012
We recently reiterated our Neutral recommendation on Abaxis Inc. (NASDAQ:ABAX) based on its dependency on distributors which makes it difficult to establish a steady distribution network overseas. The... Read More
from DailyMarkets.com
Highs & Lows: Alere, Apollo Group, and Verizon
May 11, 2012
The major market indexes are wobbling around breakeven this afternoon, as traders weigh JPMorgan's (JPM) trading blunder against an upbeat reading from the University of Michigan/Thomson Reuters... Read More
category
ALR
CE Mark For Quidel RSV+hMPV Test
March 13, 2012
Leading diagnostic test solutions provider Quidel Corporation (NASDAQ:QDEL) has won the European CE Mark for its new virus test dubbed the “Quidel Molecular RSV + hMPV Assay” designed for the detection... Read More
from DailyMarkets.com
Alere To Take Over EScreen
March 02, 2012
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently reported its binding agreement to buy eScreen for a base consideration of $270 million... Read More
from DailyMarkets.com
Quidel Beats Estimates
March 02, 2012
Leading diagnostic test solutions provider Quidel Corporation’s (NASDAQ:QDEL) fourth-quarter fiscal 2011 adjusted earnings (excluding one-time items other than stock-based compensation expense) of 8... Read More
from DailyMarkets.com
Abaxis Remains Neutral
February 28, 2012
We recently reiterated our ‘Neutral’ recommendation on Abaxis Inc. (NASDAQ:ABAX) with a target price of $28.00. Abaxis reported EPS of 13 cents in the third quarter of fiscal 2012, missing the year-ago... Read More
from DailyMarkets.com
Alere Beats In 4Q, Incurs Loss
February 10, 2012
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported fourth-quarter and fiscal 2011 adjusted earnings per share of 74 cents and $2.48,... Read More
from DailyMarkets.com
Alere’s Flu Test Gains FDA Waiver
January 27, 2012
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has received a confirmation that the U.S. Food and Drug Administration... Read More
from DailyMarkets.com
Disappointing 3Q For Abaxis
January 27, 2012
Abaxis Inc. (NASDAQ:ABAX) reported third quarter 2012 EPS of 13 cents, missing the year-ago quarter EPS by 4 cents, as well as the Zacks Consensus Estimate of 16 cents. Net sales during the quarter... Read More
from DailyMarkets.com
Abaxis Develops New Veterinary Test
December 28, 2011
Abaxis Veterinary Reference Laboratories (AVRL) Division of Abaxis, Inc. (NASDAQ:ABAX) recently announced the development of a quantitative antibody test for canine Lyme disease. The new canine Lyme... Read More
from DailyMarkets.com
FDA Nod For Quidel’s HMPV Test
December 27, 2011
Leading diagnostic test solutions provider Quidel Corporation (NASDAQ:QDEL) has won the approval of the U.S. Food and Drug Administration (“FDA”) for its new virus test dubbed the “Quidel Molecular... Read More
from DailyMarkets.com
Abaxis Expands Rapid Test Portfolio
December 23, 2011
Abaxis, Inc. (NASDAQ:ABAX), a manufacturer of point-of-care blood analysis systems for medical and veterinary markets, recently expanded its rapid diagnostics product line with the inclusion of a... Read More
from DailyMarkets.com
CE Mark For Quidel’s Strep A Test
December 08, 2011
Leading diagnostic test solutions provider Quidel Corporation (NASDAQ:QDEL) recently won the European CE Mark for its Sofia Streptococcus A (“Strep A”) test for use with its Sofia Analyzer. The product... Read More
from DailyMarkets.com
(ABAX) Alere Takes Over Arriva Medical
December 01, 2011
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health... Visit StockBlogHub to view complete post. Read More
from Stock Blog Hub
Alere Takes Over Arriva
November 30, 2011
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing... Read More
from DailyMarkets.com
Abaxis Upgraded To Neutral
November 28, 2011
Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (NASDAQ:ABAX) to Neutral with a target price... Read More
from DailyMarkets.com
Abaxis Beats, Margins Down
October 27, 2011
Abaxis Inc. (NASDAQ:ABAX) reported second quarter 2012 EPS of 15 cents, missing the year-ago quarter EPS by 2 cents, but ahead of the Zacks Consensus Estimate of 13 cents. Net sales during the quarter... Read More
from DailyMarkets.com
New York, September 29th (TradersHuddle.com) – Following are some of the top upgrades and downgrades before the market open. Upgrades FMC Technologies (<a href="h. Read More -- Read More
from TradersHuddle.com
CE Mark For Quidel HMPV Test
September 27, 2011
Leading diagnostic test solutions provider Quidel Corporation (NASDAQ:QDEL) has won the European CE Mark for its new virus test, representing another key milestone for the California-based company. The... Read More
from DailyMarkets.com
Abaxis Remains At Underperform
September 07, 2011
We reiterate our Underperform recommendation on Abaxis (NASDAQ:ABAX) with a target price of $23.00. The company’s first quarter 2012 financial results were well below the Zacks Consensus Estimates.... Read More
from DailyMarkets.com
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here